- Carbon-11 and Fluorine-18 Radiolabeled Pyridopyrazinone Derivatives for Positron Emission Tomography (PET) Imaging of Phosphodiesterase-5 (PDE5)
-
The cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 (PDE5) plays an important role in various pathologies including pulmonary arterial hypertension and cardiomyopathy. PDE5 represents an important therapeutic and/or prognostic targ
- Chekol, Rufael,Gheysens, Olivier,Ahamed, Muneer,Cleynhens, Jan,Pokreisz, Peter,Vanhoof, Greet,Janssens, Stefan,Verbruggen, Alfons,Bormans, Guy
-
supporting information
p. 486 - 496
(2017/04/26)
-
- HETEROCYCLICALLY SUBSTITUTED ARYL COMPOUNDS AS HIF INHIBITORS
-
The present application relates to novel aryl compounds with heterocyclic substituents, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention
- -
-
Paragraph 1097; 1098; 1099; 1100
(2013/08/14)
-
- GLYCINE COMPOUND
-
[Problem] The present invention provides a compound which is useful as an active ingredient of a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases. [Means for Solution] The present inventors have conducted intensive studies on a compound having a VAP-1 inhibitory activity, and as a result, they have found that a compound of the present invention or a salt thereof exhibits an excellent VAP-1 inhibitory activity and is useful for preventing and/or treating VAP-1-related diseases, in particular, diabetic nephropathy or diabetic macular edema, thereby completing the present invention. The present invention further relates to a pharmaceutical composition, in particular, a pharmaceutical composition for preventing and/or treating VAP-1-related diseases, which comprises the compound of the present invention or a salt thereof, and an excipient.
- -
-
Page/Page column 23
(2012/07/28)
-
- PURINE COMPOUNDS USED AS CB2 AGONISTS
-
A compound of the formula (I) and pharmaceutical compositions for the treatment of pain.
- -
-
Page/Page column 16
(2011/10/13)
-
- PURINE COMPOUNDS
-
A compound of the formula: and pharmaceutical compositions for the treatment or prevention of pain.
- -
-
Page/Page column 10
(2011/10/13)
-
- Radiofluorinated pyrimidine-2,4,6-triones as molecular probes for noninvasive MMP-targeted imaging
-
Matrix metalloproteinases (MMPs) are zinc- and calcium-dependent endopeptidases. Representing a subfamily of the metzincin superfamily, MMPs are involved in the proteolytic degradation of components of the extracellular matrix. Unregulated MMP expression,
- Breyholz, Hans-Joerg,Wagner, Stefan,Faust, Andreas,Riemann, Burkhard,Hoeltke, Carsten,Hermann, Sven,Schober, Otmar,Schaefers, Michael,Kopka, Klaus
-
experimental part
p. 777 - 789
(2011/01/05)
-
- Purine Compounds
-
A compound of the formula: and pharmaceutical compositions for the treatment of pain.
- -
-
Page/Page column 16-17
(2010/07/04)
-
- Imidazopyridine Kinase Inhibitors
-
The present invention provides imidazopyridine compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.
- -
-
Page/Page column 74; 118
(2009/01/20)
-
- QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER
-
The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3,Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.
- -
-
Page/Page column 90
(2008/06/13)
-
- SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS
-
The invention concerns quinoline derivatives of Formula (I) wherein each of Z1, m, R1, n, R3, Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.
- -
-
-